[{"orgOrder":0,"company":"Myst Therapeutics","sponsor":"Turnstone Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Myst Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Myst Therapeutics \/ Turnstone Biologics","highestDevelopmentStatusID":"1","companyTruncated":"Myst Therapeutics \/ Turnstone Biologics"}]

Find Clinical Drug Pipeline Developments & Deals by Myst Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          DIA 2025
                          Not Confirmed
                          DIA 2025
                          Not Confirmed

                          Details : Turnstone gains full access to this technology, the complete R&D capabilities of Myst along with existing development collaborations, and a pipeline of tumor infiltrating lymphocyte programs with the lead candidate expected to enter the clinic this year.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          January 20, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Turnstone Biologics

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank